http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107837282-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0d44338a9983e0302c286cb9d319ff9
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
filingDate 2016-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685253980351b754f8ecf6867157fabf
publicationDate 2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107837282-A
titleOfInvention Applications of the Isovitexin in anti-bacterial drug is prepared
abstract The present invention relates to applications of the Isovitexin in anti-bacterial drug is prepared, belong to field of medicaments.Isovitexin have the function that it is very strong suppress Escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, proteus, neogenesis cryptococcus, therefore Isovitexin can be used as has antibacterial compound, and be expected to be applied in related drugs are prepared.Purposes of the Isovitexin of the present invention in anti-bacterial drug is prepared belongs to first public, because framework types belong to brand-new framework types, and it is unexpectedly strong for bacteriostatic activity, in the absence of the possibility that any enlightenment is provided by other compounds, possess prominent substantive distinguishing features, while obviously there is significant progress for the preventing and treating of bacterium infection.
priorityDate 2016-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503345
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID562
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426209774
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1280
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14179013
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1472306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37768
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590486
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1549008
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505877
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID456201
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505924
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280965
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1472306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534922
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1280
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162350
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID562

Total number of triples: 39.